Home / Categories / Miscellaneous / Samples / Throwback Thursday
Click to view full size image
Click here for details on how to download this file to your desktop.

Humira

Now reimbursed by all provinces across Canada

In moderate to severe Crohn’s disease, demonstrated to sustain power, sustain remission.

[...]

HUMIRA
adalimumab

HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy, including corticosteroids and/or immunosuppressants. HUMIRA is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

HUMIRA is indicated for reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). HUMIRA can be used alone or in combination with methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs).

When used a$ first-line treatment in recently diagnosed patients who have not been previously treated with MTX, HUMIRA should be given in combination with MTX. HUMIRA can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is contraindicated.

HUMIRA is indicated for reducing the signs and symptoms of active arthritis and inhibiting the progression of structural damage and improving the physical function in adult psoriatic arthritis (PsA) patients. HUMIRA can be used in combination with MTX in patients who do not respond adequately to MTX alone. HUMIRA is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy.

HUMIRA is indicated for the treatment of adult patients with chronic moderate to severe psoriasis (Ps) who are candidates for systemic therapy.

For patients with chronic moderate plaque psoriasis, HUMIRA should be used after phototherapy has been shown to be ineffective or inappropriate.


Abbott
A Promise for Life


Brand: Humira
Country/Market: Canada, North America
Target: Healthcare Professional (HCP)
Tagline: A promise for life
Size/duration: Double-page spread
Publication/Aired:
CMAJ - April 2009


See more Humira ads here
Rate this file (Current rating : 5 / 5 with 1 votes)
About Subscriptions Contact us Twitter LinkedIn